Characteristics of 1415 adult patients with previously untreated AML by inclusion in the present study
| . | Included patients (N = 175) . | Excluded patients (N = 1240) . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Sex | ||||
| Female | 77 | 44 | 567 | 46 |
| Male | 98 | 56 | 673 | 54 |
| Race/ethnicity | ||||
| Asian, non-Hispanic | 8 | 5 | 19 | 2 |
| Black, non-Hispanic | 18 | 10 | 118 | 10 |
| Native American | 0 | 0 | 5 | 0.4 |
| Pacific Islander | 2 | 1 | 2 | 0.2 |
| White, Hispanic | 5 | 3 | 24 | 2 |
| White, non-Hispanic | 141 | 81 | 1048 | 85 |
| Unknown | 0 | 0 | 24 | 2 |
| FAB class (local diagnosis) | ||||
| M1 | 39 | 22 | 270 | 22 |
| M2 | 53 | 30 | 357 | 29 |
| M3 | 6 | 3 | 99 | 8 |
| M4 | 49 | 28 | 279 | 23 |
| M5 | 15 | 9 | 95 | 8 |
| M6 | 0 | 0 | 41 | 3 |
| M7 | 1 | 1 | 11 | 1 |
| M0 | 7 | 4 | 20 | 2 |
| Other | 4 | 2 | 46 | 4 |
| AML, NOS | 1 | 1 | 22 | 2 |
| AML onset | ||||
| De novo | 59 | 34 | 243 | 20 |
| Secondary | 29 | 17 | 117 | 9 |
| Unknown | 87 | 50 | 880 | 71 |
| Study and treatment arm | ||||
| S8600 AD | 30 | 17 | 555 | 45 |
| S8600 hAD | 16 | 9 | 262 | 21 |
| S9031 AD | 21 | 12 | 97 | 8 |
| S9031 AD+G-CSF | 19 | 11 | 97 | 8 |
| S9126 AD | 3 | 2 | 22 | 2 |
| S9126 AD+CyA | 2 | 1 | 25 | 2 |
| S9333 AD | 43 | 25 | 119 | 10 |
| S9500 3+7+3 | 41 | 23 | 63 | 5 |
| Age, y | Median: 56 | Range: 18-84 | Median: 53 | Range: 15-88 |
| Marrow blasts, % | Median: 76 | Range: 15-99 | Median: 66 | Range: 0-99 |
| WBCs, 1000/μL | Median: 42.9 | Range: 0.8-274 | Median: 12.6 | Range: 0.4-416 |
| Peripheral blasts, % | Median: 44 | Range: 0-94 | Median: 30 | Range: 0-99 |
| . | Included patients (N = 175) . | Excluded patients (N = 1240) . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Sex | ||||
| Female | 77 | 44 | 567 | 46 |
| Male | 98 | 56 | 673 | 54 |
| Race/ethnicity | ||||
| Asian, non-Hispanic | 8 | 5 | 19 | 2 |
| Black, non-Hispanic | 18 | 10 | 118 | 10 |
| Native American | 0 | 0 | 5 | 0.4 |
| Pacific Islander | 2 | 1 | 2 | 0.2 |
| White, Hispanic | 5 | 3 | 24 | 2 |
| White, non-Hispanic | 141 | 81 | 1048 | 85 |
| Unknown | 0 | 0 | 24 | 2 |
| FAB class (local diagnosis) | ||||
| M1 | 39 | 22 | 270 | 22 |
| M2 | 53 | 30 | 357 | 29 |
| M3 | 6 | 3 | 99 | 8 |
| M4 | 49 | 28 | 279 | 23 |
| M5 | 15 | 9 | 95 | 8 |
| M6 | 0 | 0 | 41 | 3 |
| M7 | 1 | 1 | 11 | 1 |
| M0 | 7 | 4 | 20 | 2 |
| Other | 4 | 2 | 46 | 4 |
| AML, NOS | 1 | 1 | 22 | 2 |
| AML onset | ||||
| De novo | 59 | 34 | 243 | 20 |
| Secondary | 29 | 17 | 117 | 9 |
| Unknown | 87 | 50 | 880 | 71 |
| Study and treatment arm | ||||
| S8600 AD | 30 | 17 | 555 | 45 |
| S8600 hAD | 16 | 9 | 262 | 21 |
| S9031 AD | 21 | 12 | 97 | 8 |
| S9031 AD+G-CSF | 19 | 11 | 97 | 8 |
| S9126 AD | 3 | 2 | 22 | 2 |
| S9126 AD+CyA | 2 | 1 | 25 | 2 |
| S9333 AD | 43 | 25 | 119 | 10 |
| S9500 3+7+3 | 41 | 23 | 63 | 5 |
| Age, y | Median: 56 | Range: 18-84 | Median: 53 | Range: 15-88 |
| Marrow blasts, % | Median: 76 | Range: 15-99 | Median: 66 | Range: 0-99 |
| WBCs, 1000/μL | Median: 42.9 | Range: 0.8-274 | Median: 12.6 | Range: 0.4-416 |
| Peripheral blasts, % | Median: 44 | Range: 0-94 | Median: 30 | Range: 0-99 |
FAB indicates French-American-British; NOS, not otherwise specified; AD, standard-dose cytarabine and daunomycin; hAD, high-dose cytarabine and daunomycin; G-CSF, granulocyte colony-stimulating factor; Cy-A, cyclosporin A; 3+7+3, AD followed by 3 days of high-dose cytarabine; and WBCs, white blood cells.